Add like
Add dislike
Add to saved papers

Serum CA 19.9 Levels in Patients With Benign and Malignant Disease: Correlation With the Serum Protein Electrophoretic Pattern.

Anticancer Research 2019 Februrary
AIM: To confirm that the carbohydrate antigen 19.9 (CA 19.9) protein can be evaluated by determining changes in the β2 zone in protein electrophoresis.

MATERIALS AND METHODS: A total of 75 patients (64 with cancer, 11 with benign diseases) with abnormal serum CA 19.9 level were included.

RESULTS: Patients with cancer had significantly higher serum CA 19.9 concentrations than those with benign diseases (p<0.001). Similar CA 19.9 levels were observed in patients with normal (median 1129 U/ml), weakly positive (median 699 U/ml) and positive (2333 U/ml) β2 fraction in protein electrophoresis. In contrast, changes in the protein pattern of the β2 fraction were related to an inflammatory pattern with significantly higher C-reactive protein concentration (p<0.0001), independently of serum CA 19.9 level.

CONCLUSION: The intensity of the β2 fraction in protein electrophoresis is related to inflammation and not to CA 19.9 in patients with cancer or other diseases.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app